Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 14, 2018Open Access

The efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia.

View Full Paper
Ask AI
Bookmark
Share

Authors

YHYueting HuangXLX F LiuYCY F Chen

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Huang et al. (2018) studied this question.

synapsesocial.com/papers/6a96ac0323945b2448823752https://doi.org/10.3760/cma.j.issn.0253-2727.2018.01.007
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multicentre, randomised phase<scp>III</scp>study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia2016 · 79 citations
  2. 2Morbidity and mortality in adults with idiopathic thrombocytopenic purpura2001 · 499 citations
  3. 3Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group2008 · 2,709 citations
  4. 4Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study2012 · 338 citations
  5. 5Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia2012 · 553 citations